Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Virtual Neuro and Ophthalmology Conference, April 27-28, 2022.
| NEW YORK, April 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Virtual Neuro and Ophthalmology Conference, April 27-28, 2022.
Raj Mehra, Ph.D., Chairman and CEO and Tim Whitaker, MD, Chief Medical Officer, will participate in a fireside chat on Wednesday, April 27th at 12:00 PM ET. For registration: B. Riley Securities’ Virtual Neuro and Ophthalmology Conference About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases. For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference. Contact Information: Anthony Marciano Mike Moyer Managing Director
SOURCE Seelos Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:SEEL |
View original content to download multimedia:
